SUNY Downstate Health Sciences University

Kansas City University and HCA Midwest Health Forge Key Academic Partnership

Retrieved on: 
Wednesday, November 1, 2023
Medical Affairs Bureau, Armed Forces Post Graduate Medical Institute, DO, Education, Centerpoint Medical Center, Heart, Overland Park Regional Medical Center, SUNY Downstate Health Sciences University, Physician, HCA Healthcare, Research, KCU, Learning, Growth, Medicine, GME, Student, Partnership, Kansas City University, Menorah Medical Center, Graduate medical education, Galen College of Nursing, Research Medical Center, Nursing, Alta Bates Summit Medical Center, Osteopathic medicine in the United States, Kansas City metropolitan area

KANSAS CITY, Mo., Nov. 1, 2023 /PRNewswire/ -- Kansas City University (KCU), the largest medical school in Missouri and the sixth largest medical school in the nation, and HCA Midwest Health, Kansas City's premier healthcare provider, recently announced a principle affiliation that will strengthen the training of tomorrow's physicians, today.

Key Points: 
  • KANSAS CITY, Mo., Nov. 1, 2023 /PRNewswire/ -- Kansas City University (KCU), the largest medical school in Missouri and the sixth largest medical school in the nation, and HCA Midwest Health, Kansas City's premier healthcare provider, recently announced a principle affiliation that will strengthen the training of tomorrow's physicians, today.
  • Many HCA Midwest Health physicians will receive academic faculty appointments with the university as well.
  • KCU is a leading health sciences university which includes a proud legacy as Kansas City Missouri's first medical school.
  • HCA Healthcare is a leader in clinical and medical education, and its affiliates – including HCA Midwest Health – currently include 66 teaching hospitals.

Global Platform Study Presents Results to Guide Care of Severely Ill Patients With COVID-19 Using Routinely Available Drugs – Simvastatin and Vitamin C

Retrieved on: 
Wednesday, October 25, 2023
Science, Research, Pharmaceutical, Health, COVID-19, Infectious Diseases, Hospitals, Clinical Trials, WHO, Urinary tract infection, Survival, FRCP, Patient, Vitamin C, Simvastatin, Royal Victoria Hospital, Montreal, Bronchopneumonia, MPH, Global Coalition Against Pneumonia, Oregon Health & Science University, University, Respiratory tract infection, JAMA, Professor, Vitamin, Multimedia, Queen's University Belfast, University of Pittsburgh School of Medicine, Learning, Critical Care Medicine (journal), COVID, Clinical trial, Intensive care unit, Hospital, NEJM, Probability, Pittsburgh, European Society of Clinical Microbiology and Infectious Diseases, Wilfrid Sellars, SUNY Downstate Health Sciences University, Hospice and palliative medicine, Intensive care medicine, Royal Victoria Hospital, UPMC, Consultant, Ohio State University Wexner Medical Center, Pharmaceutical industry, Dietary supplement, MD

Vitamin C is widely available around the world and was used in some settings for the treatment of COVID-19.

Key Points: 
  • Vitamin C is widely available around the world and was used in some settings for the treatment of COVID-19.
  • Through harmonizing two clinical trials – REMAP-CAP and LOVIT-COVID – over 2500 patients in 20 countries took part, including both critically ill and non-critically ill patients with COVID-19 in hospital.
  • It was shown that high dose vitamin C did not improve outcomes for patients.
  • Intravenous Vitamin C for Patients Hospitalized with COVID-19: Two Harmonized Randomized Clinical Trials.

Synlogic Announces Publication of Synpheny-1 Phase 2 Study of Synthetic Biotic for Phenylketonuria in Nature Metabolism

Retrieved on: 
Thursday, September 28, 2023
University of Pittsburgh, University, Oregon Health & Science University, Safety, University of Florida, Drug, Vanderbilt University, AbbVie, Washington University in St. Louis, Nature Metabolism, PKU, University of Colorado, Mount Sinai Hospital, Patient, SUNY Downstate Health Sciences University, Sondheim (surname), Treatment, Pharmaceutical industry, Phenylketonuria

CAMBRIDGE, Mass., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, today announced the publication of results from its Synpheny-1 Phase 2 study of its drug candidates, labafenogene marselecobac (SYNB1934) and SYNB1618 in patients with phenylketonuria (PKU) in the journal Nature Metabolism.

Key Points: 
  • CAMBRIDGE, Mass., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, today announced the publication of results from its Synpheny-1 Phase 2 study of its drug candidates, labafenogene marselecobac (SYNB1934) and SYNB1618 in patients with phenylketonuria (PKU) in the journal Nature Metabolism.
  • The publication, entitled “Efficacy and Safety of a Synthetic Biotic for Treatment of Phenylketonuria: a Phase 2 Clinical Trial” is now available online at https://www.nature.com/articles/s42255-023-00897-6 .
  • The paper includes a comprehensive review of the data, showing clinically meaningful, dose-dependent reductions in plasma phenylalanine (Phe).
  • “These positive results build on a body of data supporting the role of labafenogene marselecobac for patients with PKU,” said Dr. Neal Sondheimer, Head of Clinical Development at Synlogic.

Eye Care Organizations Unite to Save Sight of Premature Infants Using Artificial Intelligence

Retrieved on: 
Thursday, September 21, 2023
Retina, Telehealth, Partnership, National Eye, Life, DL, Oregon Health & Science University, Oxygen, Ophthalmology, Research, Paratriathlon, Eye, Patient, Premature, Orbis International, Risk, Child, SUNY Downstate Health Sciences University, ROP, Artificial intelligence, Diagnosis, National Eye Institute, FDA, National Institute for Health and Care Excellence, Disease, Pharmaceutical industry, Nursing, Birth control, Medical device, Orbis, AI

NEW YORK, Sept. 21, 2023 /PRNewswire/ -- Eye care nonprofit Orbis International is excited to announce a new strategic partnership with Siloam Vision to use the company's cloud-based telemedicine platform to expand access to eye care and prevent blindness in premature infants living in hard-to-reach communities. Siloam Vision's artificial intelligence (AI) platform helps diagnose retinopathy of prematurity (ROP) – the leading cause of childhood blindness globally.

Key Points: 
  • Siloam Vision's artificial intelligence (AI) platform helps diagnose retinopathy of prematurity (ROP) – the leading cause of childhood blindness globally.
  • Orbis and Siloam Vision have aligned missions to make sure no child starts out life blind from an avoidable cause.
  • We are excited to partner with Orbis to help save the sight of more preterm babies in hard-to-reach-communities."
  • Orbis is working to ensure eye care professionals everywhere can access these tools for free.

Arcutis Submits Roflumilast Cream 0.15% Supplemental New Drug Application to the FDA for the Treatment of Atopic Dermatitis in Adults and Children Ages 6 Years and Older

Retrieved on: 
Tuesday, September 12, 2023
PDE4, Flare, Disease, Irritant, Prevalence, Week, Oregon Health & Science University, Ethanol, Dermatitis, Parent, George Washington University School of Engineering and Applied Science, New Drug Application, George Washington University School of Medicine & Health Sciences, Propylene glycol, Skin, Atopic dermatitis, FAAD, Excipient, Oregon Health Plan, IGA, MCR, Shanda, MD, Patient, Risk, SUNY Downstate Health Sciences University, Outline of health sciences, AD, FDA, MPH, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Safety, Success, Vaccine, Pharmaceutical industry, Dermatology, Doctor of Philosophy

In clinical studies, once-daily roflumilast cream provided rapid clearance of the disease.

Key Points: 
  • In clinical studies, once-daily roflumilast cream provided rapid clearance of the disease.
  • Roflumilast cream is uniquely formulated with HydroARQ Technology™ as a non-greasy emollient cream that absorbs quickly and does not disrupt the skin barrier.
  • “Topical roflumilast cream was intentionally formulated with the atopic dermatitis patient in mind, and does not contain excipients that disrupt skin-barrier integrity or are common contact allergens.
  • I would like to thank the team at Arcutis for their incredible hard work and dedication,” added Watanabe.

Nuvectis Pharma to Host KOL Event to Discuss Its Two Precision Medicine Clinical-Stage Drug Candidates, NXP800 and NXP900

Retrieved on: 
Wednesday, September 6, 2023
KOL, University, Oregon Health & Science University, Platinum, University of Arizona College of Medicine – Tucson, Doctor of Philosophy, University of California, San Diego, Patient, SUNY Downstate Health Sciences University, FACS, Ovarian cancer, Cancer, Knight Cancer Institute, Safety, Pharmaceutical industry, FACOG, MD

Fort Lee, NJ, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced it will host a virtual KOL event to discuss its two clinical-stage drug candidates, NXP800 and NXP900, on Thursday, September 14, 2023 at 10:00am ET.

Key Points: 
  • Fort Lee, NJ, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced it will host a virtual KOL event to discuss its two clinical-stage drug candidates, NXP800 and NXP900, on Thursday, September 14, 2023 at 10:00am ET.
  • To register for the event, please click here .
  • The event will feature Bradley J. Monk, MD, FACS, FACOG (University of Arizona College of Medicine) and Ramez N. Eskander, MD (University of California San Diego) who will discuss the clinical development opportunity for NXP800 in ovarian cancer, and specifically in patients with platinum resistant, ARID1a-mutated ovarian carcinoma, a patient population that is currently being enrolled into an ongoing Phase 1b clinical trial in which the safety and preliminary efficacy of NXP800 is being investigated, and Gordon Mills, MD, PhD (Knight Cancer Institute, Oregon Health & Science University) who will discuss the clinical development opportunities for NXP900 as the Phase 1a dose escalation study is about to commence.
  • A live question and answer session will follow the formal presentations.

Moximed’s MISHA™ Knee System Treats First Commercial Patients in United States

Retrieved on: 
Wednesday, September 6, 2023
General Health, Health, Medical Devices, Surgeon, University, Terminal, Orthopedic surgery, Oregon Health & Science University, Quality of life, Arthropathy, Hamstring, Cartilage, Trial of the century, Pain, OA, Hospital for Special Surgery, Rehabilitation, Motion, Walking, Standard of care, Patient, Physician, School, SUNY Downstate Health Sciences University, HSS, ISA, Hospital, Ageing, Meniscus, FDA, Chronic pain, Osteoarthritis, University of Virginia, Female, Knee, Dentistry, DRS

Until the MISHA Knee System became available in April 2023, physicians and many patients had limited treatment options when conservative treatments failed.

Key Points: 
  • Until the MISHA Knee System became available in April 2023, physicians and many patients had limited treatment options when conservative treatments failed.
  • Prior to the MISHA Knee System being available, I had no good options for this patient.
  • For these patients, total knee replacement is a reluctant option, as it is an end-stage treatment for end-stage disease.
  • OA patients without end-stage disease seek options that preserve their knee, activity level, and quality of life.

The Inner Circle Acknowledges, Haris Choudry as a Distinguished Healthcare Provider for his contributions to the fields of Physiatry and Orthopedics

Retrieved on: 
Tuesday, August 29, 2023
University of Oklahoma College of Medicine, Bachelor, PM, University, Education, Amputation, Arthritis, Disability, Ligament, Spinal cord, American Board of Physical Medicine and Rehabilitation, Associated Students of the University of Washington, Public, Sophie Choudry, Quality of life, Physical medicine and rehabilitation, Johns Hopkins School of Medicine, Medicine, Brain, Mentorship, Multimedia, SUNY Downstate Medical Center, PM&R, Inner circle, SUNY Downstate Health Sciences University, American Board of Commissioners for Foreign Missions, Public health, Medical director, MD, Union of the Physically Impaired Against Segregation, Joint, Knowledge, Hospital, R, Health, Chronic pain, Clinical, Tendon, International Society, Nursing, Orthopedic surgery, Biochemistry, Rehabilitation

NEW YORK, Aug. 28, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Haris Choudry is acknowledged as a Distinguished Healthcare Provider for his contributions to the fields of Physiatry and Orthopedics.

Key Points: 
  • NEW YORK, Aug. 28, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Haris Choudry is acknowledged as a Distinguished Healthcare Provider for his contributions to the fields of Physiatry and Orthopedics.
  • Dr. Choudry pursued higher education at the University of Oklahoma where he earned a Bachelor's degree in Biochemistry.
  • He then continued at the University of Oklahoma College of Medicine where he received his medical degree and completed his residency in physical medicine & rehabilitation at SUNY Downstate Health Sciences University.
  • Physiatrists treat a wide variety of medical conditions affecting the brain, spinal cord, nerves, bones, joints, ligaments, muscles, and tendons.

The Inner Circle Acknowledges, Joey Kevin Grochmal as a Pinnacle Life Member for his contributions to the Medical and Educational Fields

Retrieved on: 
Monday, August 21, 2023
Faculty, Royal college, University, Education, Health, Tetraplegia, Baylor College of Medicine, Stroke, Neoplasm, Medical college, Physician, Spinal cord, Infection, University of Alberta Faculty of Medicine and Dentistry, Baylor University, Spine, Head, Rehabilitation, Brain, Mentorship, Multimedia, Sympathetic nervous system, Disorder, Assistant, Inner circle, Science, SUNY Downstate Health Sciences University, Congress of Neurological Surgeons, Royal College of Physicians and Surgeons of Canada, American Association of Neurological Surgeons, Master of Science, Nervous system, Medical College of Wisconsin, Surgeon, Diagnosis, Knowledge, Society, Nursing, Dentistry, Medicine, Neuroscience, MD, Neurosurgery

HOUSTON, Aug. 21, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Joey Kevin Grochmal is acknowledged as a Pinnacle Life Member for his contributions to the Medical and Educational Fields.

Key Points: 
  • HOUSTON, Aug. 21, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Joey Kevin Grochmal is acknowledged as a Pinnacle Life Member for his contributions to the Medical and Educational Fields.
  • Dr. Grochmal pursued higher education at the University of Alberta in Canada where he received a Bachelor of Science degree in Neuroscience.
  • The doctor capped his scholarship by finishing a fellowship in spine surgery at the Medical College of Wisconsin in 2018.
  • Dr. Grochmal is a Fellow of the Royal College of Physicians and Surgeons of Canada (FRCPSC).

Evie Ring Establishes Medical Advisory Board Furthering its Commitment to Bringing a Medical-Grade Wearable to Women

Retrieved on: 
Thursday, August 10, 2023
Science, University, University of California, Berkeley, Seattle University, Modern Healthcare, Less, FACP, Sleep, Ageing, Oregon Health & Science University, Menopause, Woman, FACOG, Inflammation, Stress management, Harvard Business Review, Evie, MS, Oregon Health and Science University Center for Women's Health, CCMS, Oxygen saturation (medicine), UC, RSW, SUNY Downstate Health Sciences University, Providence Portland Medical Center, Health, FDA, MPH, Regulation of tobacco by the U.S. Food and Drug Administration, Mental health, Social work, Food, Pharmaceutical industry, Nursing, Doctor of Philosophy, MD, MSW

PLEASANTON, Calif., Aug. 10, 2023 /PRNewswire/ -- Today, Movano Health (Nasdaq: MOVE), a purpose-driven healthcare solutions company at the intersection of medical and consumer devices and makers of the Evie Ring, announced the formation of its Medical Advisory Board. The initial panel is composed of healthcare industry subject matter experts in women's health, mental health, and sleep, who will serve as trusted advisors to the Evie team regarding the development of its medical-grade smart ring for women and provide insights to establish Evie as a highly credible health and wellness resource.

Key Points: 
  • The inaugural members of the Medical Advisory Board include:
    Dr. Mary Claire Haver, MD, FACOG, CCMS is a board-certified OB/GYN, author and entrepreneur who has devoted her practice to women's health.
  • She has helped thousands of women going through perimenopause and menopause actualize their health and wellness goals by creating The Galveston Diet integrated wellness program.
  • She emerged with an evidence-based program so women could wisely invest in their most undervalued asset, their health.
  • "To develop a wearable that is truly medical grade, we needed to make sure we involved the experts.